1. [Bone liposclerosing myxofibrous tumor. Case presentation and literature review].
- Author
-
Técualt-Gómez R, Atencio-Chan A, Cario-Méndez AG, Amaya-Zepeda RA, Balderas-Martinez J, and González-Valladares JR
- Subjects
- Aged, 80 and over, Bone Neoplasms pathology, Femoral Neoplasms pathology, Fibroma diagnosis, Fibroma pathology, Fibrous Dysplasia of Bone diagnosis, Fibrous Dysplasia of Bone pathology, Humans, Lipoma pathology, Male, Myxoma pathology, Xanthomatosis diagnosis, Xanthomatosis pathology, Bone Neoplasms diagnosis, Femoral Neoplasms diagnosis, Lipoma diagnosis, Myxoma diagnosis
- Abstract
The bone liposclerosing myxofibrous tumor (LSMFT) was initially described by Ragsdale in 1986 as a polymorphic fibroosseous bone lesion with a mix of histologic elements that include lipoma, fibroxanthoma, myxoma, myxofibroma, fat necrosis, ischemic ossification, areas of fibrous dysplasia, and infrequent presence of cartilage or cystic changes. The most frequently reported location is the intertrochanteric area of the femur. Radiologically it is a lytic, geographic lesion, with well-defined margins and usually sclerotic. In some cases findings include mineralization inside the lesion or a certain degree of expansion to the contour. The close relationship between LSMFT and fibrous dysplasia has been described based on the histologic characteristics and the presence of the Gsα mutation. Another hypothesis of the etiology of the lesion is the reaction of fibrous dysplasia to stress.
- Published
- 2015